Investor Alert

London Markets Open in:

Oct. 18, 2021, 8:19 a.m. EDT

Revance's stock falls 35% after FDA says it won't approve the company's frown-line injection

Shares of Revance Therapeutics Inc. (NAS:RVNC) tumbled 35.3% in premarket trading on Monday after the company said Friday that the Food and Drug Administration had declined to approve Revance's application for a frown-line treatment. The FDA issued a complete response letter that the company received Oct. 15, citing issues with Revance's manufacturing facilities. Revance said it plans to address those concerns. Revance's stock is down 19.9% for the year, while the broader S&P 500 (S&P:SPX) is up 19.0%.

Link to MarketWatch's Slice.